Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of dexmedetomidine for maintenance of general anesthesia
ChiCTR2200058005Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of dexmedetomidine in malignant neoplasm of abdomen, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: ED50 of dexmedetomidine for maintenance of general anesthesia. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
malignant neoplasm of abdomen
Beyond the preview
Go deeper on ChiCTR2200058005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058005.